HC Wainwright & Co. Reiterates Neutral on Durect
$DRRX
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. analyst Ed Arce reiterates Durect (NASDAQ:DRRX) with a Neutral.
Save time and jump to the most important pieces.
HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00
Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously
4 - DURECT CORP (0001082038) (Issuer)
4 - DURECT CORP (0001082038) (Issuer)
4 - DURECT CORP (0001082038) (Issuer)
CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceutical co
- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif., Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended June 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigene
CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceu
Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form
SC 13G - DURECT CORP (0001082038) (Subject)
SC 13G - DURECT CORP (0001082038) (Subject)
SC 13G/A - DURECT CORP (0001082038) (Subject)
CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceutical co
CUPERTINO, Calif., Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dys
- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO, Calif. , Sept. 25, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the trea
8-K - DURECT CORP (0001082038) (Filer)
8-K/A - DURECT CORP (0001082038) (Filer)
8-K - DURECT CORP (0001082038) (Filer)
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires. "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT. "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January
CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,
HC Wainwright & Co. analyst Ed Arce reiterates Durect (NASDAQ:DRRX) with a Neutral.
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved